ABB Strengthens Commitment to Canada
24.5.2017 15:32:00 EEST | Business Wire | Press release
ABB today officially inaugurated its new $90 million state-of-the-art Canadian headquarters and Customer Innovation Center, which will serve 700 employees who were previously spread across six locations in Greater Montreal. Campus Montreal houses research and development, manufacturing, assembly and testing for ABB's energy value chain.
This Smart News Release features multimedia. View the full release here: http://www.businesswire.com/news/home/20170524005652/en/
New ABB Canada headquarters in Montreal (Photo: Business Wire)
“The new headquarters reaffirms ABB’s commitment to Canada as a growth market and an important customer base,” said ABB CEO Ulrich Spiesshofer. “It strengthens our capacity to provide our leading offering to our customers and support them with the digital transformation of their operations. We are in the midst of the Fourth Industrial Revolution, and this site has been designed to enable our workforce to unlock value for Canadian enterprises.”
Campus Montreal is the home of ABB’s Customer Innovation Center, which showcases ABB Ability, the company’s comprehensive digital offering. By combining ABB’s deep domain expertise with network connectivity and the latest digital technologies and innovations, ABB Ability creates powerful solutions and services that address real business problems and produce tangible business opportunities.
“The new campus allows greater collaboration with our business partners and with the academic and research sectors,” said Nathalie Pilon, President of ABB Canada. “The latest technology from ABB is driving energy efficiency and powering Canada’s innovation ecosystem in so many ways. In addition to showing what ABB Ability can do, the headquarters is also home to our new ABB North American Centre of Excellence in E-Mobility.”
The ABB North American Centre of Excellence in E-Mobility was created to share expertise with Canadian customers and stakeholders in the field of electric-powered transportation technologies. It will support the development of environmentally friendly, energy-efficient transport networks, including electric buses and trains, and will bring together transit operators, power utilities and engineering experts to address challenges related to building smart cities and sustainable mobility solutions for Canada.
In line with ABB’s vision of sustainability, the campus is expected to be LEED-certified Silver for its sustainable approach to design, construction and operation.
This new site is an example of ABB’s broad and longstanding engagement in Canada. In parallel, the company announced a number of major Canadian projects. Among these was an agreement to modernize 10 large seagoing ships for the Canadian Coast Guard, equipping them with upgraded propulsion systems. When combined with ABB's Remote Diagnostic Service for maritime operations, the upgrade will enable the Coast Guard to extend the service life of the ships by 20 years.
In another development, ABB was named the Key Technical Supplier for Nemaska Lithium’s new mine and processing plant. ABB will provide overall project management, design and engineering for the complete electrification and automation of the production sites.
In addition, ABB has announced that it will provide an integrated substation for an important data center operated by Hypertec in Quebec. To meet growing demand, the new substation will increase the facility’s existing power supply from 25 to 120 kilovolts.
ABB has more than 100 years of experience in innovation in Canada and was responsible for the construction of a major portion of the country’s power grid. ABB Canada has 4,000 employees in 55 locations and is ranked as one of Canada’s Best Employers in 2017.
ABB (ABBN: SIX Swiss Ex) is a pioneering technology leader in electrification products, robotics and motion, industrial automation and power grids, serving customers in utilities, industry and transport & infrastructure globally. Continuing more than a 125-year history of innovation, ABB today is writing the future of industrial digitalization and driving the Energy and Fourth Industrial Revolutions. ABB operates in more than 100 countries with about 132,000 employees. www.abb.com
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: http://www.businesswire.com/news/home/20170524005652/en/
Contact information
For more information, please contact:
ABB Ltd
Media
Relations
Phone: +41 43 317 65 68
Email: media.relations@ch.abb.com
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Galderma Receives U.S. FDA Approval for Differin ® Epiduo ® Acne Gel Prescription-to-OTC Switch22.5.2026 19:25:00 EEST | Press release
Galderma (SIX: GALD), the pure-play dermatology category leader, today announced that the United States (U.S.) Food and Drug Administration (FDA) has approved Differin® Epiduo® Acne Gel (Adapalene 0.1% and Benzoyl Peroxide 2.5% Acne Treatment) for over-the-counter (OTC) use in ages 12 years and older, marking a significant Prescription-to-OTC transition in acne care. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260522074280/en/ The U.S. FDA approves Differin® Epiduo® Acne Gel Prescription-to-OTC switch This milestone represents yet another example of Galderma’s unique Integrated Dermatology strategy, demonstrating how proven innovations from its Therapeutic Dermatology portfolio can further strengthen its Dermatological Skincare offerings. The Prescription‑to‑OTC transition highlights Galderma’s scale and expertise in successfully commercializing dermatology innovations across the full spectrum of acne care. With the appro
Avanzanite Bioscience’s Partner Agios Announces PYRUKYND® (mitapivat) Approval in the European Union for Adults with Thalassaemia22.5.2026 17:18:00 EEST | Press release
Avanzanite Bioscience B.V., a rapidly growing commercial-stage European specialty pharmaceutical company focused on rare diseases, today reported that its partner, Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a commercial-stage biopharmaceutical company headquartered in Cambridge, Massachusetts focused on delivering innovative medicines for patients with rare diseases, announced that the European Commission has granted marketing authorisation for PYRUKYND® (mitapivat), an oral pyruvate kinase (PK) activator, in adults for the treatment of anaemia associated with transfusion-dependent and non-transfusion-dependent alpha- or beta-thalassaemia, with an orphan medicinal product designation. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260522186975/en/ Adam Plich, CEO and Co-Founder of Avanzanite Bioscience. “Thalassaemia is a complex, chronic and multisystem disease characterised by anaemia, ineffective erythropoiesis and haemo
ICE Brent and ICE WTI Perpetual Futures to Launch on OKX22.5.2026 15:30:00 EEST | Press release
OKX, a blockchain technology and trading company serving more than 120 million customers globally,and Intercontinental Exchange (NYSE: ICE), one of the world's leading providers of financial market technology and data powering global capital markets including the New York Stock Exchange, today announced plans for OKX to launch perpetual futures based on ICE's Brent Crude and WTI Crude energy benchmarks. The products are expected to be available to trade on OKX’s platform in jurisdictions where OKX is licensed to offer perpetual futures products. The new OKX contracts represent a major step forward in expanding regulated access to global commodity markets through digital asset infrastructure. This first product collaboration between OKX and ICE comes after the companies established a strategic relationship in March 2026. ICE operates some of the world’s leading exchanges, clearing houses and market data services across energy, commodities, fixed income and equities markets. ICE’s future
Enhertu ® Recommended for Approval in the EU by CHMP for Patients with Previously Treated HER2 Positive Metastatic Solid Tumors22.5.2026 15:00:00 EEST | Press release
Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the treatment of adult patients with unresectable or metastatic HER2 positive (immunohistochemistry [IHC] 3+) solid tumors who have received prior treatment and who have no satisfactory treatment options. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from patients with HER2 positive (IHC 3+) tumors in three phase 2 trials including DESTINY-PanTumor02,DESTINY-Lung01 andDESTINY-CRC02 where Enhertu demonstrated clinically meaningful responses across a broad range of tumors. The recommendation will now be reviewed by the European Commission, which has the authority
Future Health Challenge Awards USD 300,000 to Early Detection and Population Health Sensing Tools on Sidelines of World Health Assembly22.5.2026 14:45:00 EEST | Press release
Three global teams developing early detection and real-time population health monitoring solutions have secured a total of USD 300,000 on the sidelines of the 79th World Health Assembly. The winning solutions address critical challenges in early detection, continuous population insight and more timely decision making, signalling a shift in health systems from late-stage treatment to earlier intervention. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260522587414/en/ Selected from 393 submissions across 68 countries, the winning teams were recognised through the inaugural ‘Future Health Challenge 2026: Building Anticipatory Health Systems through Population Sensing’, delivered by Future Health – A Global Initiative by Abu Dhabi in collaboration with MIT Solve. Health systems globally are facing rising costs and persistent delays in diagnosis, with many conditions still identified only after symptoms become severe. At the sam
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom